Always talk to your healthcare provider before changing your dose
In this context, it has been demonstrated that treatments with either a GLP1/Estrogen (GLP1/E) conjugate, a unimolecular GLP1/GIP (gastric inhibitory peptide) dual agonist, or a GLP1/GIP/Glucagon triagonist, markedly reduced body weight and improved diabetic complications, including hyperinsulinemia, in preclinical models of obesity in males 33,34,35
In real-world data, GLP-1RAs differ in clinical indications, uptake over time, adherence rate, typical treatment duration, dose escalation, and patient selection, all of which can introduce residual confounding and channeling bias (29, 30)
Shima Hadidchi MD carefully considers various aspects to determine which weight loss medication is best for you
57 SeiwerthS.RucmanR.TurkovicB.SeverM.KlicekR.RadicB.et al (2018)
S.MetsiosD.KitasG